Corona Remedies Ltd vs Unjha Formulations Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Corona Remedies Ltd is ₹ 1580 as of 19 Feb 10:41 . The P/E Ratio of Corona Remedies Ltd is 0 as of March 2023 .The P/E Ratio of Unjha Formulations Ltd is 0 as of March 2023 . The Market Cap of Corona Remedies Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Unjha Formulations Ltd is ₹ 0 crore as of March 2023 . The revenue of Corona Remedies Ltd for the Mar '26 is ₹ 357.48 crore as compare to the Dec '25 revenue of ₹ 344.68 crore. This represent the growth of 3.71% The revenue of Unjha Formulations Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Corona Remedies Ltd for the Mar '26 is ₹ 66.41 crore as compare to the Dec '25 ebitda of ₹ 66.32 crore. This represent the growth of 0.14% The ebitda of Unjha Formulations Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Corona Remedies Ltd changed from ₹ 29.95 crore to ₹ 45.33 crore over 8 quarters. This represents a CAGR of 23.03% The net profit of Unjha Formulations Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Corona Remedies Ltd changed from 20 % on March 2023 to 30 % on March 2025 . This represents a CAGR of 14.47% over 3 yearsThe Dividend Payout of Unjha Formulations Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Corona Remedies Ltd

Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited', a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli.
Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited'.
A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024. The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat).
The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. In 2004, Company launched the first division, and later named it as Pioneer' division in year 2010; launched Xemx (multispeciality) division in 2005.

About Unjha Formulations Ltd

Unjha Formulations Limited was established in June, 1987 as a Partnership firm for manufacturing pharmaceutical formulations in the Mehsana district of Gujarat.
The Company is a pioneer in Isabgol (Psyllium) Formulation.
The Company is in service to Isabgol (Psyllium) Ayurvedic formulation profession. The company manufactures pharmaceutical formulations like liquids, powder, tablets, capsules, injectibles, etc.
It is one of the largest manufacturers of isabgul products in India.
The company's products are classified under two divisions -- human consumption and veterinary products. Its parent company M/S Urvesh Ltd. is 100% EOU is engaged in exporting of Isabol Husk & Isabgol Powder.

FAQs for the comparison of Corona Remedies Ltd and Unjha Formulations Ltd

Which company has a larger market capitalization, Corona Remedies Ltd or Unjha Formulations Ltd?

Market cap of Corona Remedies Ltd is 10,880 Cr while Market cap of Unjha Formulations Ltd is 9 Cr

What are the key factors driving the stock performance of Corona Remedies Ltd and Unjha Formulations Ltd?

The stock performance of Corona Remedies Ltd and Unjha Formulations Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Corona Remedies Ltd and Unjha Formulations Ltd?

As of May 18, 2026, the Corona Remedies Ltd stock price is INR ₹1779.1. On the other hand, Unjha Formulations Ltd stock price is INR ₹20.11.

How do dividend payouts of Corona Remedies Ltd and Unjha Formulations Ltd compare?

To compare the dividend payouts of Corona Remedies Ltd and Unjha Formulations Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.